CMC Biologics Announces Appointment of New CEO

Claes Glassell, former CEO of Cerus Corporation, to Take Helm

COPENHAGEN, Denmark and SEATTLE, May 2, 2011 - CMC Biologics, a leading biopharmaceutical Contract Manufacturing
Organization, with operations in Copenhagen, Denmark and Seattle, Washington
USA, announced today that it has hired Claes Glassell to serve at its Chief
Executive Officer. CMC Biologics, a company with 370 employees, is committed
to delivering world class, fully integrated, biopharmaceutical process
development and manufacturing services.

(Logo: photos.prnewswire.com/prnh/20110502/SF93356LOGO)

Claes Glassell brings more than 30 years of industry experience to CMC,
most recently as CEO of Cerus Corporation and prior to that as President of
Cambrex Corp.

"We are thrilled that Claes has joined the CMC executive team," said
David Kauffmann, Chairman of the Board, CMC Biologics, and Managing Director
of European Equity Partners. "Claes has been on CMC's board of directors for
more than 5 years, and has during that time exhibited a broad range of
experience and insight of our industry. Claes' strong leadership qualities
and seasoned business understanding makes him the ideal leader to take CMC
Biologics to the next level as a leader in our fast moving industry."

"Joining the CMC Executive team at this important time in the Company's
lifecycle is a great privilege," said Claes Glassell. "The Company has,
despite a very challenging environment in recent years, been successful in
continuing to realize strong growth. Today, CMC has a very solid order book
demonstrating the strength of the Company's world class service offering,
management and science team. CMC is positioned to be a highly successful
company."

Claes Glassell joined the CMC board of directors in 2005. Claes left the
position as President & CEO of Cerus Corporation, Inc. to take on the
position as CEO of CMC Biologics. He is the former President of Cambrex
Corporation, Inc. and has previously held senior positions with Akzo Nobel
NV, Nobel Industries AB and Berol Kemi AB. His areas of expertise include 20
years of executive positions in publicly listed Life Sciences companies
responsible for bioprocessing, active ingredients business, registered
therapeutic agents and various support services.

"Having known and worked with Claes for a number of years I am delighted
that he has accepted the position as CEO of CMC," said Mads Laustsen, who is
leaving the role as CEO of CMC to take up the position as Chief Science
Officer responsible for Technology and Corporate Development. Mads will also
join the CMC Board of Directors. "As one of the founders of CMC, I think that
Claes brings the best skills and experience to ensure CMC's continued growth.
I look forward to working with Claes leading the executive team."

About CMC Biologics

CMC Biologics (www.cmcbio.com) is a leading contract development
organization that provides fully integrated biopharmaceutical development and
manufacturing services to clients around the world, from its facilities in
Europe and the USA. The Company specializes in custom services for the
scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical,
clinical and in-market API production. CMC Biologics' wide range of
integrated services includes cell line development using its proprietary
CHEF1(R)system, process development and best in class comprehensive
analytical and characterization services. CMC Biologics has fully segregated
microbial and mammalian cell culture suites and offers both stirred tank and
perfusion processes. CMC Biologics is located in Copenhagen, Denmark and
Bothell, Washington near Seattle, USA.

David Kauffmann, Chairman of CMC Biologics, +44-7768004421, david at eeplp.com